NEW YORK (GenomeWeb) – Agilent Technologies said after the close of the market on Monday that it has received notice of an unsolicited mini-tender offer by TRC Capital to purchase up to 2.5 million shares of Agilent's common stock, or about .75 percent of the company's outstanding stock, at $41.55 per share. 

Agilent is advising its shareholders to reject the offer, saying that TRC Capital has acknowledged that its share price offer is more than 4 percent below the closing price of Agilent's shares on April 15, the last trading day before the mini-tender offer commenced. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.